Umb Bank N A Decreased Its Position in Merck & Co INC (MRK) by $13.50 Million

June 21, 2018 - By Michael Collier

Merck & Co., Inc. (NYSE:MRK) LogoInvestors sentiment increased to 1 in 2018 Q1. Its up 0.06, from 0.94 in 2017Q4. It is positive, as 72 investors sold MRK shares while 603 reduced holdings. 114 funds opened positions while 561 raised stakes. 1.91 billion shares or 1.08% less from 1.93 billion shares in 2017Q4 were reported. Great West Life Assurance Can holds 3.40 million shares or 0.45% of its portfolio. Lesa Sroufe & reported 4,863 shares. Moreover, Carret Asset Mngmt Limited Liability has 0.73% invested in Merck & Co., Inc. (NYSE:MRK) for 82,004 shares. Corda Inv Mngmt Lc invested in 2.04% or 298,835 shares. Bnp Paribas Asset Holdg Sa invested in 0.46% or 1.01M shares. C World Group Inc Holdg A S holds 200,817 shares or 0.17% of its portfolio. British Columbia Mngmt Corporation holds 0.64% of its portfolio in Merck & Co., Inc. (NYSE:MRK) for 1.55M shares. Gam Ag accumulated 0.21% or 107,344 shares. The New York-based Chemung Canal Trust has invested 0.67% in Merck & Co., Inc. (NYSE:MRK). Mitsubishi Ufj reported 6.04 million shares. Edge Wealth Mngmt Lc has invested 2.27% of its portfolio in Merck & Co., Inc. (NYSE:MRK). Greenleaf reported 0.03% of its portfolio in Merck & Co., Inc. (NYSE:MRK). Dekabank Deutsche Girozentrale holds 2.21 million shares. Advisor Ltd has invested 0.6% in Merck & Co., Inc. (NYSE:MRK). Zevin Asset Management Lc stated it has 5,000 shares or 0.07% of all its holdings.

Umb Bank N A decreased its stake in Merck & Co Inc (MRK) by 52.22% based on its latest 2018Q1 regulatory filing with the SEC. Umb Bank N A sold 249,925 shares as the company’s stock rose 5.40% while stock markets declined. The institutional investor held 228,690 shares of the health care company at the end of 2018Q1, valued at $12.46 million, down from 478,615 at the end of the previous reported quarter. Umb Bank N A who had been investing in Merck & Co Inc for a number of months, seems to be less bullish one the $163.75B market cap company. The stock decreased 0.68% or $0.415 during the last trading session, reaching $60.865. About 3.15M shares traded. Merck & Co., Inc. (NYSE:MRK) has declined 9.15% since June 21, 2017 and is downtrending. It has underperformed by 21.72% the S&P500.

Umb Bank N A, which manages about $3.10B US Long portfolio, upped its stake in Ishares Tr Russell 2000 Value (IWN) by 54,110 shares to 140,630 shares, valued at $17.14 million in 2018Q1, according to the filing. It also increased its holding in Abbott Laboratories (NYSE:ABT) by 144,134 shares in the quarter, for a total of 244,384 shares, and has risen its stake in Fedex Corp (NYSE:FDX).

Analysts await Merck & Co., Inc. (NYSE:MRK) to report earnings on July, 27. They expect $1.04 EPS, up 2.97 % or $0.03 from last year’s $1.01 per share. MRK’s profit will be $2.80 billion for 14.63 P/E if the $1.04 EPS becomes a reality. After $1.05 actual EPS reported by Merck & Co., Inc. for the previous quarter, Wall Street now forecasts -0.95 % negative EPS growth.

More news for Merck & Co., Inc. (NYSE:MRK) were recently published by:, which released: “Better Buy: Celgene Corporation vs. Merck” on June 19, 2018.‘s article titled: “Alzheimer’s Disease: A History Of Drug Failures” and published on June 19, 2018 is yet another important article.

Merck & Co., Inc. (NYSE:MRK) Ratings Coverage

Among 12 analysts covering Merck \u0026 Co (NYSE:MRK), 10 have Buy rating, 0 Sell and 2 Hold. Therefore 83% are positive. Merck \u0026 Co has $7300 highest and $5500 lowest target. $66.89’s average target is 9.90% above currents $60.865 stock price. Merck \u0026 Co had 19 analyst reports since January 16, 2018 according to SRatingsIntel. The stock has “Buy” rating by SunTrust on Tuesday, January 16. On Tuesday, February 6 the stock rating was maintained by Leerink Swann with “Market Perform”. The stock of Merck & Co., Inc. (NYSE:MRK) earned “Hold” rating by Cowen & Co on Friday, April 20. The firm earned “Equal-Weight” rating on Wednesday, February 7 by Morgan Stanley. Goldman Sachs upgraded it to “Buy” rating and $7300 target in Monday, April 23 report. On Friday, March 23 the stock rating was maintained by Jefferies with “Hold”. As per Thursday, April 5, the company rating was upgraded by Barclays Capital. As per Wednesday, February 14, the company rating was maintained by Credit Suisse. The firm has “Overweight” rating by Morgan Stanley given on Tuesday, April 17. As per Tuesday, January 16, the company rating was maintained by Jefferies.

Merck & Co., Inc. (NYSE:MRK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: